JBIO Jade Biosciences, Inc.
Financings ·
Jade Biosciences agreed to a PIPE financing of about $135 million at $9.14 per share, with Jefferies, TD Cowen, Stifel and Wedbush named as placement agents, and says its cash will fund operations into the first half of 2028.
Jade Biosciences (Nasdaq: JBIO) reported a net loss of $38,169 thousand and cash of $49,929 thousand for the quarter ended March 31, 2025, a period that ended before the merger and pre-closing financing closed April 28.
Aerovate Therapeutics took the Jade Biosciences name when the deal closed on April 28, 2025. Pre-merger Jade's management team runs the combined company.
Aerovate Therapeutics, whose only drug candidate missed its Phase 2b primary endpoint, closed its merger with Jade Biosciences on April 28, 2025. Aerovate holders kept about 1.4% of the combined company, and the financing includes $95 million of converted notes.
Aerovate filed a Jade communication on March 3, 2025, under their October 30, 2024 merger agreement. The combined company is expected to trade on Nasdaq as JBIO.
Jade Biosciences is a clinical-stage biopharmaceutical company developing novel biologic therapies for patients with autoimmune diseases. Its approach is to develop biologics against emerging targets supported by third-party clinical data and to overcome shortcomings of existing candidates in potency, bioavailability, formulation and pharmacokinetic properties. Its lead candidate, JADE101, is a half-life extended monoclonal antibody targeting APRIL, which the company plans to develop initially for IgA nephropathy (IgAN). A Phase 1 trial of JADE101 in healthy volunteers in New Zealand began in August 2025, with interim data expected in the second quarter of 2026, and a Phase 2 trial in IgAN patients is planned for the middle of 2026. Its second candidate, JADE201, is a half-life extended, afucosylated monoclonal antibody targeting BAFF-R for multiple autoimmune disorders. A third candidate, JADE301, targets a pathway the company has not disclosed.
| Product or program | What it is | Stage |
|---|---|---|
| JADE101 | Half-life extended antibody targeting APRIL for IgA nephropathy | Phase 1; Phase 2 planned |
| JADE201 | Half-life extended, afucosylated antibody targeting BAFF-R for autoimmune disorders | |
| JADE301 | Monoclonal antibody targeting an undisclosed pathway |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $93.1 million | $53.2 million |
| Net income (loss) | -$127.4 million | -$69.6 million |
| Cash from operations | -$94.7 million | -$71.2 million |
| Cash and equivalents | $88.4 million | $69.4 million |
| Short-term investments | $247.7 million | $0 |
Our latest story on this, dated Oct 7, 2025: "Jade Biosciences agrees to $135 million private placement at $9.14 per share". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 14, 2025: "Jade Biosciences files Q1 financials after Aerovate merger and $334.2 million financing". The story links the filing or release it is based on. Read the story.
Jade Biosciences, Inc. trades under the ticker JBIO on NASDAQ.
Jade Biosciences, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Jade Biosciences, Inc. is 1798749. Its filings are on SEC EDGAR.
63,597,387 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-10.
Our directory records Jade Biosciences, Inc. under United States.
Our directory classifies Jade Biosciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Jade Biosciences, Inc. is US0080642061.
aibio.space lists Jade Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Jade Biosciences is a clinical-stage biopharmaceutical company developing novel biologic therapies for patients with autoimmune diseases. Its approach is to develop biologics against emerging targets supported by third-party clinical data and to overcome shortcomings of existing candidates in potency, bioavailability, formulation and pharmacokinetic properties.
JADE101: Half-life extended antibody targeting APRIL for IgA nephropathy Stage: Phase 1; Phase 2 planned.
JADE201: Half-life extended, afucosylated antibody targeting BAFF-R for autoimmune disorders
Jade Biosciences, Inc. reported a net loss of $127.4 million for the fiscal year ended Dec 31, 2025, and used $94.7 million of cash in operations, per its annual report to the SEC.
Reported a financing. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 2.02,8.01,9.01). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,2.02,7.01,9.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 1.01,2.01,2.02,3.03,4.01,5.01,5.02,5.03,5.05,5.06,7.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 8.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,7.01,8.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a merger or acquisition agreement. SEC Form 425. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,5.01,5.02,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio